BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24096118)

  • 1. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Monotherapies and Combination Therapy of Tamsulosin and Tadalafil for Treating Lower Urinary Tract Symptoms Caused by Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Meta-Analysis.
    Liu J; Zhou W; Zhang P; Zhang W; Chang C; Fu G
    Urol Int; 2024; 108(2):89-99. PubMed ID: 38081154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis.
    Fusco F; D'Anzeo G; Henneges C; Rossi A; Büttner H; Nickel JC
    PLoS One; 2015; 10(8):e0135484. PubMed ID: 26284523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia.
    Olesovsky C; Kapoor A
    Ther Adv Urol; 2016 Aug; 8(4):257-271. PubMed ID: 27928428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.
    Macoska JA; Uchtmann KS; Leverson GE; McVary KT; Ricke WA
    J Urol; 2019 Dec; 202(6):1240-1247. PubMed ID: 31188728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of L-Carnitine and Coenzyme Q10 Supplementation on Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia: A Randomized, Controlled, Clinical Trial.
    Norouzi M; Mahboobi S; Eftekhari MH; Salehipour M; Ghaem H; Mirzakhanlouei A; Mohsenpour MA
    Nutr Cancer; 2024; 76(2):207-214. PubMed ID: 38105612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Filson CP; Wei JT; Hollingsworth JM
    Urology; 2013 Dec; 82(6):1386-92. PubMed ID: 24269224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Kaplan SA; Moss J; Freedman S; Coutinho K; Wu N; Efros M; Elterman D; D'Anna R; Padron O; Robertson KJ; Lawindy S; Mistry S; Shore N; Spier J; Kaminetsky J; Mazzarella B; Cahn D; Jalkut M; Te A
    J Urol; 2023 Sep; 210(3):500-509. PubMed ID: 37555604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia.
    Rohrbough CR; Colgan B; Gasser O
    Am Fam Physician; 2024 Jan; 109(1):83-84. PubMed ID: 38227876
    [No Abstract]   [Full Text] [Related]  

  • 10. Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia.
    Govorov A; Kasyan G; Priymak D; Pushkar D; Sorsaburu S
    Cent European J Urol; 2014; 67(2):167-77. PubMed ID: 25140232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.
    Madersbacher S; Sampson N; Culig Z
    Gerontology; 2019; 65(5):458-464. PubMed ID: 30943489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical Advancements in Benign Prostatic Hyperplasia Treatments.
    Ganesan V; Agarwal D
    Curr Urol Rep; 2024 May; 25(5):93-98. PubMed ID: 38448685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms.
    Barry MJ; Cantor A; Roehrborn CG;
    J Urol; 2013 Mar; 189(3):987-92. PubMed ID: 23017510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Zhu LL; Feng ZJ; Zhou Q
    Clin Interv Aging; 2015; 10():621-2. PubMed ID: 25848238
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Müderrisoglu AE; de la Rosette JJMCH; Michel MC
    Expert Opin Drug Saf; 2023; 22(12):1213-1224. PubMed ID: 38064204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.
    Parsons JK; Schenk JM; Arnold KB; Messer K; Till C; Thompson IM; Kristal AR; ;
    Eur Urol; 2012 Aug; 62(2):234-41. PubMed ID: 22459892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of auricular acupressure combined with 5α-reductase inhibitor on short-term quality of life of patients after transurethral plasmakinetic enucleation of the prostate].
    Xue YF; Fan YX; Wang R
    Zhonghua Nan Ke Xue; 2023 Jul; 29(7):609-614. PubMed ID: 38619407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of the Prostatic Urethral Lift for Lower Urinary Tract Symptoms: Symptom Relief, Flow Improvement, and Preservation of Sexual Function in Men With Benign Prostatic Hyperplasia.
    Shore N
    Curr Bladder Dysfunct Rep; 2015; 10(2):186-192. PubMed ID: 25984251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term tadalafil once daily in Chinese men with erectile dysfunction: a 2-year final analysis of a post-marketing, multicenter, randomized, open-label trial.
    Jiang H; Zhao LM; Yan S; Liu JH; Zhu ZH; Luo JD; Dai YT; Li FB; Lin HC; Zhang ZC
    Asian J Androl; 2024 Jan; 26(3):282-7. PubMed ID: 38284776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: Tukey's test.
    Darweish E; Mohamed AR
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Jan; 305():123551. PubMed ID: 37857076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.